Suggested Remit: To appraise the clinical and cost effectiveness of nivolumab with platinum-based chemotherapy within its marketing authorisation for advanced unresectable, recurrent or metastatic oesophageal cancer that has not been previously treated.
Status In progress
Process STA 2018
ID number 2712

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
30 September 2020 - 28 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 January 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance